Physician profile
Mitchell G Miglis
NPI 1972779411
$51,186.31
in general payments reported to CMS, 2019-2025
9 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.39 · 2022: $8,598 · 2023: $15K · 2024: $5,963 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,240 · Food and Beverage: $3,262 · Honoraria: $3,200 · Travel and Lodging: $2,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,662.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,240.00 |
| Food and Beverage | $3,262.43 |
| Honoraria | $3,200.00 |
| Travel and Lodging | $2,182.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $46,343.61 | 2019-2025 | Xywav |
| Lundbeck LLC | $3,200.00 | 2025 | |
| Argenx US, INC. | $696.14 | 2023 | Vyvgart |
| Pfizer INC. | $550.00 | 2022 | |
| Harmony Biosciences LLC | $355.95 | 2022-2025 | Wakix |
| Alnylam Pharmaceuticals INC. | $40.61 | 2023 | Amvuttra |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Miglis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.